Pharmacokinetics of isoliquiritigenin and its metabolites in rats: Low bioavailability is primarily due to the hepatic and intestinal metabolism

Planta Medica

Volumn 79, Issue 17, 2013, Pages 1656-1665

  Lee, Yu Kyung ^a   Chin, Young Won ^a   Bae, Jin Kyung ^a   Seo, Jun Su ^a   Choi, Young Hee ^a  

^a Dongguk University   (South Korea)

Author keywords

Fabaceae; glucuronidated metabolites; Glycyrrhiza glabra; isoliquiritigenin; liquiritigenin; pharmacokinetics

Indexed keywords

GLUCURONIDATED ISOLIQUIRITIGENIN; GLUCURONIDATED LIQUIRITIGENIN; ISOLIQUIRITIGENIN; LIQUIRITIGENIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LARGE INTESTINE; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SMALL INTESTINE; TIME TO MAXIMUM PLASMA CONCENTRATION;

FABACEAE; GLYCYRRHIZA; GLYCYRRHIZA GLABRA; RATTUS;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHALCONES; FLAVANONES; GLYCYRRHIZA; INTESTINES; KIDNEY; LIVER; MALE; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84889596807     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0033-1350924     Document Type: Article

References (35)

1. Chin Y. W., Jung H. A., Liu Y., Su B. N., Castoro J. A., Keller W. J., Pereira M. A., Kinghorn A. D. Anti-oxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra). J Agric Food Chem: 2007; 55 4691 4697 (Pubitemid 46960894)
2. Haraguchi H., Ishikawa H., Mizutani K., Tamura Y., Kinoshita T. Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata. Bioorg Med Chem: 1998; 6 339 347 (Pubitemid 28144484)
3. Kim J. Y., Park S. J., Yun K. J., Cho Y. W., Park H. J., Lee K. T. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. Eur J Pharmacol: 2008; 584 175 184
4. Lee C. K., Son S. H., Park K. K., Park J. H., Lim S. S., Chung W. Y. Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. J Pharm Sci: 2008; 106 444 451 (Pubitemid 351468597)
5. Baba M., Asano R., Takigami I., Takahashi T., Ohmura M., Okada Y., Sugimoto H., Arika T., Nishino H., Okuyama T. Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol Pharm Bull: 2002; 25 247 250 (Pubitemid 39592115)
6. Tamir S., Eizenberg M., Somjen D., Izrael S., Vaya J. Estrogen-like activity of glabrene and other constituents isolated from licorice root. J Steroid Biochem Mol Biol: 2001; 78 291 298 (Pubitemid 32953624)
7. Cuendet M., Oteham C. P., Moon R. C., Pezzuto J. M. Quinone reductase induction as a biomarker for cancer chemoprevention. J Nat Prod: 2006; 69 460 463
8. Ross D., Kepa J. K., Winski S. L., Bcall H. D., Anwar A., Siegel D. NAD(P)H: Quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact: 2000; 129 77 97 (Pubitemid 32061055)
9. Kim S. C., Byun S. H., Yang C. H., Kim C. Y., Kim J. W., Kim S. G. Cytoprotective effects of Glycyrrhizae radix extract and its active component liquiritigenin against cadmium-induced toxicity (effects on bad translocation and cytochrome c-mediated PARP cleavage). Toxicology: 2004; 197 239 251 (Pubitemid 38368117)
10. Kim Y. W., Ki S. H., Lee J. R., Lee S. J., Kim C. W., Kim S. C., Kim S. G. Liquiritigenin, an aglycone of liquiritin in Glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sufoximine. Chem Biol Interact: 2006; 161 125 138 (Pubitemid 43776630)
11. Kim Y. W., Zhao R. J., Park S. J., Lee J. R., Cho I. J., Yang C. H., Kim S. G., Kim S. C. Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-kappaB-dependent iNOS and proinflammatory cytokines production. Br J Pharmacol: 2008; 154 165 173 (Pubitemid 351620405)
12. Kim Y. W., Kang H. E., Lee M. G., Hwang S. J., Kim S. C., Lee C. H., Kim S. G. Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes. Am J Physiol Gastrointest Liver Physiol: 2009; 296 G372 G381
13. De Smet P. A., Brauwers J. R. Pharmacokineitc evaluation of herbal remedies: basic introduction, applicability, current status and regulatory needs. Clin Pharmacokinet: 1997; 32 427 436 (Pubitemid 27243646)
14. Guo J., Liu A., Cao H., Luo Y., Pezzuto J. M., van Breemen R. B. Biotransformation of the chemopreventive agent 4,2′,4′- trihydrozychalcone (isoliguiritigenin) by UDP-glucuronosyltransferases. Drug Metab Dispos: 2008; 36 2104 2112
15. Guo J., Liu D., Nikolic D., Zhu D., Pezzuto J. M., van Breemen R. B. In vitro metabolism of isoliquiritigenin by human liver microsomes. Drug Metab Dispos: 2008; 36 461 468 (Pubitemid 351185761)
16. Tan G., Lou Z., Dong X., Li Q., Liao W., Zhu Z., Chai Y. Urinary metabolites of isoliquiritigenin in Wistar rats using UHPLC-TOF-MS-based xenometabolomics. Chromatographia: 2011; 74 341 348
17. Kroemer H. K., Klotz U. Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet: 1992; 23 292 310
18. Fromm M. F., Botsch S., Keinkele G., Evers J., Kroemer H. K. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. Eur J Clin Pharmacol: 1995; 48 279 283
19. Han S. Y., Chin Y. W., Choi Y. H. A new approach for pharmacokinetic studies of natural products: measurement of isoliquiritigenin levels in mice plasma, urine and feces using modified automated dosing/blood sampling system. Biomed Chromatogr: 2013; 27 741 749
20. Shimamura H., Nakai S., Yamamoto K., Hitomi N., Yumioka E. Biliary and urinary metabolites of liquiritigenin in rat. J Pharmacogn: 1990; 44 265 268
21. Kang H. E., Jung H. J., Cho Y. K., Kim S. H., Sohn S. I., Baek S. R., Lee M. G. Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs and animal scale-up. J Pharm Sci: 2009; 98 4327 4342
22. Li L. H., Dong H., Zhao F., Tang J., Chen X., Ding J., Men H. T., Luo W. X., Du Y., Ge J., Tan B. X., Cao D., Liu J. Y. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil. Eur J Cancer: 2013; 49 1752 1760
23. Nahrstedt A., Butterweck V. Lessons learned from herbal medicinal products: the example of St. JohnÊs Wort. J Nat Prod: 2010; 73 1015 1021
24. Simmler C., Hajirahimkhan A., Lankin D. C., Bolton J. L., Jones T., Soejarto D. D., Chen S. N., Pauli G. F. Dynamic residual complexity of the isoliquiritigenin-liquiritigenin interconversion during bioassay. J Agric Food Chem: 2013; 61 2146 2157
25. Davis B., Morris T. Physiological parameters in laboratory animals and humans. Pharm Res: 1999; 10 1093 1095
26. Mitruka B. M., Rawnsley H. M. Clinical biochemical and hematological reference values in normal experimental animals and normal humans. 2nd edition. New York, NY Masson Publishing USA Inc.: 1987; 113
27. Kang H. E., Cho Y. K., Jung H. Y., Choi K. Y., Sohn S. I., Baek S. R., Lee M. G. Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect. Xenobiotica: 2009; 39 465 475
28. Lee M. G., Chiou W. L. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm: 1983; 11 623 660
29. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for industry: drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations, U.S. Washington, DC CDER, FDA: 2012
30. Choi Y. H., Lee U., Lee B. K., Lee M. G. Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2. Br J Pharmacol: 2010; 161 815 829
31. Choi Y. H., Lee U., Suh J. H., Kim Y. G., Choi E. Y., Oh E., Lee M. G. Pharmacokinetics and first-pass effects of epsilon-acetamidocaproic acid after administration of zinc acexamate in rats. Xenobiotica: 2010; 40 485 498
32. Litterst C. L., Mimnaugh E. G., Regan R. L., Gram E. Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species. Drug Metab Dispos: 1975; 3 259 265
33. Chiou W. L. New calculation method of mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci: 1979; 68 1067 1069 (Pubitemid 9242727)
34. Gibaldi M., Perrier D. Pharmacokinetics. 2nd edition. New York, NY Marcel-Dekker: 1982
35. Kim S. H., Choi Y. M., Lee M. G. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm: 1993; 21 1 17 (Pubitemid 23261727)